Actively Recruiting
Phase 2 Study of LY4005130 IV Treatment in Adults Aged 18 to 50 with Severe Alopecia Areata
Led by Eli Lilly and Company · Updated on 2026-08-06
60
Participants Needed
30
Research Sites
17 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the effects of LY4005130 in adults with severe alopecia areata, a condition causing significant hair loss. This phase 2 study compares LY4005130 with a placebo to see how well the drug works and how well participants tolerate it. Blood tests will be used to understand how the body processes the drug and its effects. Participants will receive either LY4005130 or a placebo, both administered intravenously into a vein. The study follows a randomized, double-blind design, meaning neither participants nor researchers know who receives the drug or placebo. The study lasts about 48 weeks, including screening. During the study, participants will undergo regular assessments including blood tests and scalp biopsies to track changes in hair loss severity and gene expression. The main measurement is the percentage of participants reaching a certain improvement in hair loss by week 24. Safety and side effects will be closely monitored throughout the study period.
CONDITIONS
Brief Title
A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
Research Team
T
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
P
Physicians interested in becoming principal investigators please contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
